866-997-4948(US-Canada Toll Free)

Urinary Tract Infections (UTI) - Pipeline Assessment and Market Forecasts to 2017

Published By :

GlobalData

Published Date : Dec 2010

Category :

Diseases & Conditions

No. of Pages : 40 Pages


GlobalDatas report, Urinary Tract Infections Pipeline Assessment and Market Forecasts to 2017, is an essential source of information and analysis on the global urinary tract infections market. The report identifies key trends shaping and driving the global urinary tract infections market, and also provides insight into the prevalent competitive landscape and the emerging players expected to alter the market position of the current market leaders. Most importantly, the report provides valuable insight into the pipeline products in the global urinary tract infections segment. 

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts

GlobalDatas analysis suggests that the global Urinary Tract Infection (UTI) market was worth $1.14billion in 2009. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 3.7% for the next eight years to reach $1.3billion by 2017. The market is expected to be driven by the increase in usage of newly launched antibiotics for the treatment of complicated urinary tract infections and the increase in the prevalence and diagnosis of urinary tract infections. The patent expiry of one of the most efficacious drugs, Levaquin, in 2010 is expected to drive market revenues down. The FDA has recently approved Sandozs generic version of Levofloxacin in 2010. The impact of patent expiry is expected to be softened by the increase in revenue contribution of recently launched carbapenems for the treatment of complicated urinary tract infections.

Scope

The report identifies key trends shaping and driving the global urinary tract infections market. The scope of the report includes: 

  • Annualized global urinary tract infections market revenues data from 2001 to 2009, forecast forward for eight years to 2017. 
  • Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan. 
  • Pipeline analysis data split across different phases by mechanism of action and emerging trends. Key classes of antibiotics in the pipeline includecell wall synthesis inhibitor, dihydrofolate reductase inhibitor, topoisomerase inhibitor, colonizes the vaginal mucosa and to secrete substances that inhibit the growth of microbial pathogens, restores the susceptibility of Gram-negative pathogens which are resistant to ceftazidime, bactericidal and anti-infectives. 
  • Analysis of the current and future competition in the global UTIs market. Key market players covered include , Osel Inc, Achaogen , Cubist Pharmaceuticals, Novexel Inc (AstraZeneca), MerLion Pharmaceuticals GmbH, Tedec-Meiji Farma, S.A. and NovaBay Pharmaceuticals, Inc 
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future of the UTI market.

Reasons to buy

The report will enhance your decision making capability in a rapid and time sensitive manner. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying companies with the most promising product candidates in the pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global UTI market. 
  • Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global UTI market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidation, investments and strategic partnerships.
  • Whats the next big thing in the global UTI market landscape? Identify, understand and capitalize.
Table of content

1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5

2 Urinary Tract Infection: Introduction 6
2.1 GlobalData Pipeline Report Guidance 6

3 Urinary Tract Infection Therapeutics: Market Characterization 7
3.1 Overview 7
3.2 Urinary Tract Infection Therapeutics Market Size 7
3.3 Urinary Tract Infection Therapeutics Market Forecast and CAGR 9
3.4 Drivers and Barriers for the Urinary Tract Infection Therapeutics Market 10
3.4.1 Drivers for the Urinary Tract Infection Therapeutics Market 10
3.4.2 Barriers for the Urinary Tract Infection Therapeutics Market 10
3.5 Opportunity and Unmet Need 11
3.6 Key Takeaway 12

4 Urinary Tract Infection: Competitive Assessment 13
4.1 Overview 13
4.2 Strategic Competitor Assessment 13
4.3 Product Profiles of the Major Marketed Products for Urinary Tract Infection 14
4.3.1 Doribax (Doripenem) 14
4.3.2 Ciprofloxacin 15
4.3.3 Levaquin (levofloxacin) 17
4.3.4 Monurol (Fosfomycin Tromethamine) 18
4.3.5 Macrobid (Nitrofurantoin) 19
4.3.6 Bactrim/Septra (trimethoprim/sulfamethoxazole) 20
4.4 Key Takeaway 21

5 Urinary Tract Infection Therapeutics: Pipeline Assessment 22
5.1 Overview 22
5.2 Strategic Pipeline Assessment 22
5.2.1 Technology Trends Analytic Framework 22
5.3 Urinary Tract Infection Promising Drugs Under Clinical Development 23
5.4 Molecule Profile for Promising Drugs Under Clinical Development 24
5.4.1 CXA-101 24
5.4.2 NXL104/ceftazidime 24
5.4.3 Finafloxacin 25
5.5 Urinary Tract Infection Market Clinical Pipeline by Mechanism of Action 26
5.6 Urinary Tract Infection Therapeutics Pipeline Pipeline by Clinical Phases of Development 27
5.6.1 Urinary Tract Infection Therapeutics Phase III Clinical Pipeline 27
5.6.2 Urinary Tract Infection Therapeutics Phase II Clinical Pipeline 28
5.6.3 Urinary Tract Infection Therapeutics Preclinical Pipeline 28
5.6.4 Discontinued / Suspended Drugs for Urinary Tract Infections 28
5.7 Key Takeaway 29

6 Urinary Tract Infection: Implications for Future Market Competition 30

7 Urinary Tract Infection Therapeutics Market: Future Players in the Urinary Tract Infection Therapeutics Market 31
7.1 Introduction 31
7.2 Osel Inc. 31
7.2.1 Company Overview 31
7.2.2 UTI Portfolio 32
7.3 Cubist Pharmaceuticals 32
7.3.1 Company Overview 32
7.3.2 Business Description 32
7.3.3 Urinary Tract Infection Therapeutics Portfolio 33
7.4 AstraZeneca 33
7.4.1 Company Overview 33
7.4.2 UTI Portfolio 33
7.5 MerLion Pharmaceuticals Pte Ltd 34
7.5.1 Company Overview 34
7.5.2 UTI Portfolio 34

8 UTI Market: Appendix 35
8.1 Market Definition 35
8.2 Abbreviations 35
8.3 Research Methodology 36
8.3.1 Coverage 36
8.3.2 Secondary Research 36
8.3.3 Forecasting 36
8.3.4 Primary Research 39
8.3.5 Expert Panels 39
8.4 Contact Us 39
8.5 Disclaimer 40
8.6 Sources 40

List of Table


Table 1: Urinary Tract Infection Therapeutics Market, Global, Revenues ($m), 20012009 8
Table 2: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecast ($m), 20092017 9
Table 3: Comparison of Current Marketed Therapeutic Products for Urinary Tract Infection 21
Table 4: Urinary Tract Infection Therapeutics Market, Most Promising Drugs Under Clinical Development 23
Table 5: Urinary Tract Infection Therapeutics Pipeline, Phase III, 2010 27
Table 6: Urinary Tract Infection Therapeutics Pipeline, Phase II, 2010 28
Table 7: Urinary Tract Infection Therapeutics Pipeline, Phase I, 2010 28
Table 8: Urinary Tract Infection Therapeutics Pipeline, Preclinical, 2010 28
Table 9: Urinary Tract Infection Therapeutics Pipeline, Discontinued / Suspended Drugs, 2010 28
Table 10: Osel Inc. Urinary Tract Infection Pipeline 32
Table 11: Cubist Pharmaceuticals, Urinary Tract Infection Therapeutics Pipeline 33
Table 12: AstraZeneca PLC Urinary Tract Infection Therapeutics Pipeline 33
Table 13:MerLion Pharmaceuticals Pte Ltd, Urinary Tract Infection Therapeutics Pipeline 34

List of Chart


Figure 1: Urinary Tract Infection Therapeutics Market, Global, Revenues ($m), 20012009 8
Figure 2: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecast ($m), 20092017 9
Figure 3: Opportunity and Unmet Need in the Urinary Tract Infection Therapeutics Market 11
Figure 4: Strategic Competitor Assessment of the Marketed Products for Urinary Tract Infection 14
Figure 5: Technology Trends Analytic Framework of the Urinary Tract Infection Therapeutics Pipeline 22
Figure 6: Technology Trends Analytic Framework of the Urinary Tract Infection Therapeutics Pipeline Description 23
Figure 7: Urinary Tract Infection Therapeutics Market, Pipeline by Mechanism of Action (%) 26
Figure 8: Urinary Tract Infection Therapeutics Pipeline by Phases of Development 27
Figure 9: Implications for Future Market Competition in the Urinary Tract Infection Market 30
Figure 10: Urinary Tract Infection Therapeutics Market , Pipeline by Company 31
Figure 11: GlobalData Market Forecasting Model 38

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *